

AU Desai D D; Krishnan M R; Swindle J T; Marion T N
 CS Department of Microbiology and Immunology, University of Tennessee,
 Memphis 38163..
 NC AI 26833 (NIAID)
 BRSG-RR05423 (NCRR)
 AI 07238 (NIAID)
 SO JOURNAL OF IMMUNOLOGY, (1993 Aug 1) 151 (3) 1614-26.
 Journal code: IFB. ISSN: 0022-1767.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
 EM 199310
 AB Spontaneous anti-DNA antibodies in autoimmune mice have the
 characteristics of antibody produced by Ag-specific, clonally selective B
 cell stimulation. The nature of the somatically derived antibody V region
 structures recurrent among spontaneous anti-DNA antibodies suggests that
 DNA or DNA-protein complexes may provide the antigenic stimulus for
 autoimmune anti-DNA antibody. In order to test this hypothesis directly,
 we have immunized normal, nonautoimmune-predisposed mice with complexes
 formed with DNA and an **immunogenic**, DNA-binding peptide. The
 highly **immunogenic** peptide, Fus1, forms an internal domain of a
 128-amino acid **ubiquitin-fusion** protein from
 Trypanosoma cruzi. DNA-Fus1 complexes formed with native calf thymus DNA
 induced anti-DNA antibody in normal, nonautoimmune-predisposed mice that
 is similar in isotype and specificity to spontaneous anti-DNA antibody in
 (NZB x NZW)F1 autoimmune mice. The progressive nature of the development
 of dsDNA specificity in the immunized mice was also analogous to what is
 observed in the spontaneous anti-DNA antibody response of autoimmune (NZB
 X NZW)F1 mice. DNA-Fus1 immunized mice that produced IgG that bound to
 dsDNA had low to moderate levels of proteinuria and glomerular deposits
 of
 IgG. This experimental immunization system may be useful for
 understanding
 the immunologic basis for autoimmunity to DNA.

=> d his

(FILE 'HOME' ENTERED AT 12:56:37 ON 11 AUG 2000)

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE' ENTERED AT 13:01:10 ON
 11 AUG 2000

L1 19243 S UBIQUITIN
 L2 2065 S L1 AND (CHIMER? OR FUSION# OR HYBRID#)
 L3 232205 S L2 AND VACCINE OR IMMUNOGENIC OR IMMUNE RESPONSE
 L4 48 S L2 AND (VACCINE OR IMMUNOGENIC OR IMMUNE RESPONSE OR ADJUVAN
 L5 26 DUP REM L4 (22 DUPLICATES REMOVED)
 L6 214 S UBIQUITIN FUSION PROTEIN?
 L7 4 S L6 AND VACCINE
 L8 131 S L2 AND (VACCINE OR IMMUNOGENIC OR IMMUNE RESPONSE OR ADJUVAN
 L9 65 DUP REM L8 (66 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 13:15:10 ON 11 AUG 2000

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE' ENTERED AT 13:20:42 ON
 11 AUG 2000

FILE 'STNGUIDE' ENTERED AT 13:20:44 ON 11 AUG 2000

FILE 'MEDLINE, BIOSIS, CANCERLIT, CAPLUS, EMBASE' ENTERED AT 13:21:45 ON
 11 AUG 2000

FILE 'STNGUIDE' ENTERED AT 13:21:46 ON 11 AUG 2000

Ubiquitin

epitope or vaccine# or immunogenic or
immune response or adjuvant or antigen##

ubiquitin + (fusion or chimera? or hybrid?)

L3 + N-terminus##

L3 + (stimulat? or elicit?)

file hits - dgene, genbank, biotecabs
uspatfull, windex